Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.71 |
| ▸ | NPC1 | O15118 | 6/20 | 0.71 |
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.61 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.56 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10242069 | 0.87 | KMT2A (0.71) | KMT2ANPC1RAB9AFKBP5PKM | |
| SCHEMBL28622654 | 0.86 | RAB9A (0.93) | KMT2ANPC1RAB9AFKBP5MAPT | |
| SCHEMBL11793228 | 0.84 | KMT2A (0.73) | KMT2ANPC1RAB9APKMMAPT | |
| SCHEMBL4701247 | 0.84 | NPC1 (0.68) | KMT2ANPC1RAB9AMEN1SMN1; SMN2 | |
| SCHEMBL6778190 | 0.83 | KMT2A (0.71) | KMT2ANPC1RAB9AFKBP5MAPT | |
| SCHEMBL1924651 | 0.83 | KCNK3 (0.66) | NPC1RAB9AMAPTSMN1; SMN2KCNK3 | |
| SCHEMBL2853227 | 0.82 | ALDH1A1 (0.64) | KMT2ANPC1RAB9AFKBP5PKM | |
| SCHEMBL3241551 | 0.82 | KMT2A (0.69) | KMT2ANPC1RAB9AFKBP5MAPT | |
| SCHEMBL6346820 | 0.82 | KMT2A (0.65) | KMT2ANPC1RAB9AFKBP5PKM | |
| SCHEMBL6054992 | 0.82 | NPC1 (0.78) | KMT2ANPC1RAB9AFKBP5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104277051-B | 4 aminothiophenes simultaneously [3,2 C] carboxylic acid derivates of pyridine 7 | 霍夫曼-拉罗奇有限公司 | 2017-06-09 | — | — | CN | disclosed |
| EP-1926737-B1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-03-15 | — | — | EP | disclosed |
| CN-101263145-B | 4-amino-thieno [3,2-C ] pyridine-7-carboxylic acid derivatives | HOFFMANN LA ROCHE | 2015-02-25 | — | — | CN | disclosed |
| CN-104277051-A | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | HOFFMANN LA ROCHE | 2015-01-14 | — | — | CN | disclosed |
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
| CN-101263145-A | 4-amino-thieno [3, 2-C ] pyridine-7-carboxylic acid derivatives | HOFFMANN LA ROCHE (CH) | 2008-09-10 | — | — | CN | disclosed |
| EP-1926737-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031428-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BARTKOVITZ DAVID J | 2007-03-15 | — | — | US | disclosed |
| EP-1633715-A1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | Pfizer Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004108676-A1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BRAF, RAF1, MAP3K7 | KMT2A 1605/4885NPC1 3084/4885RAB9A 1577/4885 |
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | KMT2A 2092/4885NPC1 2343/4885RAB9A 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.